Funding: NonePotential conflicts of interest: None
1445-5994/asset/IMJ_left.gif?v=1&s=722ef184f9aa72bae1325726c13455ad3dbfce2e)
1445-5994/asset/IMJ_right.gif?v=1&s=6f6ad9c8c9af5b4790d0d9c33600f5165960a8dd)
Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms
Article first published online: 15 JUL 2008
DOI: 10.1111/j.1445-5994.2008.01712.x
© 2008 The Authors Journal compilation © 2008 Royal Australasian College of Physicians
Additional Information
How to Cite
Buchholz, S., Morrow, A. F. and Coleman, P. L. (2008), Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms. Internal Medicine Journal, 38: 602–606. doi: 10.1111/j.1445-5994.2008.01712.x
Publication History
- Issue published online: 15 JUL 2008
- Article first published online: 15 JUL 2008
- Received 23 July 2007; accepted 17 December 2007.
- Abstract
- Article
- References
- Cited By
Keywords:
- atypical antipsychotic;
- diabetes mellitus;
- diabetic ketoacidosis;
- hyperosmolar hyperglycaemic syndrome
Abstract
Diabetic ketoacidosis and hyperglycaemic hyperosmolar syndrome are rare, but potentially fatal complications of antipsychotic-associated hyperglycaemia. The mechanisms for this remain unclear, but are probably multifactorial. The suggested reasons include drug-induced weight gain and adiposity, development of the metabolic syndrome, antagonism of serotonin (5-hydroxytryptamine) receptors, drug-induced leptin resistance, dyslipidaemia mediated pancreatic β-cell damage and hepatocyte transcription factor dysregulation. Patients with schizophrenia are known to be at a higher genetic risk of developing diabetes mellitus and cardiovascular disease. This review emphasizes a rare case of hyperosmolar hyperglycaemic syndrome in a young man with schizophrenia and discusses proposed mechanisms for the development of antipsychotic-associated diabetes mellitus.